The lay press has focused a lot of attention on the use of ketamine as a potentially rapidly acting treatment for depression. But are psychiatrists really ready to offer ketamine as a treatment alternative for mood disorders? An expert weighs in.
There is rapidly escalating interest in drugs that target the glutamatergic neurotransmitter system, especially NMDA receptor modulators. The hope is that they will fill the large unmet need for rapid-acting antidepressant medications with efficacy in treatment-resistant patients.
By clicking Accept, you agree to become a member of the UBM Medica Community.